Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 1492Cisplatin 1415Paclitaxel 1319Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1111Bevacizumab 1031Fluorouracil 895Doxorubicin 792Dexamethasone 748Rituximab 720Capecitabine 717Oxaliplatin 701pembrolizumab 680Etoposide 678Irinotecan 636Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 560Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 428Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × MAC321 × Clear all
NCT00063219 2009-08-21

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00063427 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
45 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡